相关实验视频
Updated: Jul 7, 2025

09:46
Accessing the Cytotoxicity and Cell Response to Biomaterials
Published on: July 8, 2021
3.7K
链接到X的低酸性血症:有针对性的治疗是否会改变牙损伤?
Anusha Abdullah1, Sabina Noreen Wuersching2, Maximilian Kollmuss2
1Department of Oral and Maxillofacial Surgery and Facial Plastic Surgery, Ludwig Maximilians University, 80337 Munich, Germany.
Journal of clinical medicine
|December 23, 2023
概括
与X相关的低酸血症 (XLH) 会导致牙问题. 布罗苏马布治疗对骨问题有希望,但其对牙的影响需要进一步调查.
科学领域:
- 遗传学和内分泌学
- 口腔和牙和面部医学
背景情况:
- 链接到X的低度血症 (XLH) 是一种罕见的遗传疾病,影响牙和气泡骨.
- 牙损伤,包括和牙缺陷,通常是XLH的初始诊断标志.
研究的目的:
- 审查与X相关的低酸血症相关的牙特征 (表型).
- 分析目前和新兴的XLH治疗方法,特别强调它们对牙健康的影响.
主要方法:
- 文献综述总结了关于XLH的现有研究.
- 对治疗干预的分析,重点是布罗苏马布及其对牙科症状的影响.
- 综合有关牙科表型和治疗结果的数据.
主要成果:
- 遗传学发现为像Burosumab这样的向XLH疗法铺平了道路.
- 布罗苏马布已证明在改善骨问题,疼痛和酸盐代谢方面具有有效性.
- 布罗苏马布对牙损伤的影响仍在调查中,最近的研究中发现的结果各不相同.
结论:
- 布罗苏马布通过解决潜在的病理生理学,代表了XLH向治疗的重大进步.
- 进一步的研究至关重要,以充分理解和优化Burosumab和其他治疗方法对XLH患者的牙科益处.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
171
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
171
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
161
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
161
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K

